Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trialToru Mukohara(National Cancer Center Hospital East), Patricia LoRusso(Yale University)Nature MedicineJune 1, 202410.1038/s41591-024-03060-0Cited by 50SaveCiteExport RISWatch citationsRelated PapersCombination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells|Scientific Reports|2020|86